PTP4A2 and sarcoma: In the current study with Tp53 deficiency tumor models, we did not observe any impact on the expression of p53 targets or apoptosis upon Prl2 deletion in sarcoma or thymic lymphoma from both Tp53-H and Tp53-null tumors.